Organogenesis appoints Prathyusha Duraibabu to board, regains Nasdaq audit committee compliance

Organogenesis Holdings Inc.

Prathyusha Duraibabu appointed independent director effective Nov 19, 2021; also joins audit committee.
Board now has eight members; appointment restores compliance with Nasdaq Listing Rule 5605(c)(2)(A).
Ms. Duraibabu received 11,340 RSUs vesting in equal annual installments over three years.
She is CFO of Sangamo Therapeutics; brings 24+ years in tech/healthcare and CPA qualification.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Prathyusha Duraibabu

Independent Director

ORGO · Organogenesis Holdings Inc.

Effective: 2021-11-19
Filed: November 22, 2021, 6:59 PM ET

Prathyusha Duraibabu had been appointed by the board of directors to serve as an independent director of the Company effective as of November 19, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Prathyusha Duraibabu was appointed as Independent Director at Organogenesis Holdings Inc..

Action: appointed
Role: Independent Director

Exact text from the filing

Prathyusha Duraibabu had been appointed by the board of directors to serve as an independent director of the Company effective as of November 19, 2021.

View on SEC.gov

Organogenesis Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-336764

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.